Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of “Buy” from Analysts

Niagen Bioscience, Inc. (NASDAQ:NAGE) has been given an average rating of “Buy” by the five research firms that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $13.42.

A number of equities research analysts recently weighed in on NAGE shares. Wall Street Zen raised shares of Niagen Bioscience from a “buy” rating to a “strong-buy” rating in a research report on Monday. Canaccord Genuity Group boosted their price target on shares of Niagen Bioscience from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, June 10th. HC Wainwright boosted their price target on shares of Niagen Bioscience from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Monday, August 11th. Finally, Roth Capital reissued a “buy” rating and issued a $23.00 price target (up from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th.

Institutional Investors Weigh In On Niagen Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming purchased a new stake in shares of Niagen Bioscience in the fourth quarter valued at about $39,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Niagen Bioscience in the fourth quarter valued at about $53,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Niagen Bioscience in the fourth quarter valued at about $67,000. ProShare Advisors LLC purchased a new stake in shares of Niagen Bioscience in the fourth quarter valued at about $74,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in shares of Niagen Bioscience in the fourth quarter valued at about $94,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

Niagen Bioscience Price Performance

Shares of NAGE opened at $9.90 on Tuesday. Niagen Bioscience has a 1-year low of $3.10 and a 1-year high of $14.69. The stock has a market cap of $789.53 million, a PE ratio of 47.15 and a beta of 2.22. The firm has a fifty day moving average price of $10.71 and a 200 day moving average price of $8.77.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The firm had revenue of $31.12 million during the quarter, compared to analysts’ expectations of $28.55 million.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.